Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. blood sugar
Show results for
Products
Services
Software
Applications

Companies


Refine by

Blood Sugar Articles & Analysis

79 news found

Advanced Instruments’ acquisition of Nova Biomedical completed

Advanced Instruments’ acquisition of Nova Biomedical completed

Following regulatory approval, Advanced Instruments, a wholly-owned subsidiary within Patricia Industries, has now completed its acquisition of Nova Biomedical, a global provider of analytical instruments and consumables for the biopharmaceutical and clinical markets. The enterprise value amounts to USD 2.2bn. Patricia Industries has contributed USD 1.6bn in financing. The remainder of the ...

ByArtel, Inc. by Advanced Instruments


Advanced Instruments to acquire and merge with Nova Biomedical

Advanced Instruments to acquire and merge with Nova Biomedical

Patricia Industries’ subsidiary Advanced Instruments, a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, today announced the execution of a definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology ...

ByAdvanced Instruments


Protheragen-ING Unveils Its Most Popular Active Pharmaceutical Ingredients

Protheragen-ING Unveils Its Most Popular Active Pharmaceutical Ingredients

By enhancing insulin production, Semaglutide enables exploration into methods of regulating blood sugar levels, making it a focal point for researchers investigating metabolic regulation. ...

ByProtheragen-ING


Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Diabetes mellitus, a chronic condition characterized by elevated blood sugar levels, affects millions worldwide and poses serious health risks including cardiovascular disease, kidney failure, and nerve damage. ...

ByAce Therapeutics


Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

These agents work by various means ranging from increasing insulin sensitivity to promoting urine glucose excretion, in order to safely lower blood sugar levels and promote diabetic patients’ outcomes. Advancements in Mental Health with Antipsychotic APIs Protheragen-ING’s antipsychotic APIs are for the serious conditions of schizophrenia and bipolar ...

ByProtheragen-ING


Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Semaglutide represents a paradigm shift in the treatment of type 2 diabetes, as it targets the root causes of the disease rather than solely focusing on lowering blood sugar levels. Unlike traditional diabetes medications, Semaglutide has been shown to improve glycemic control, promote weight loss, and reduce the risk of cardiovascular events in individuals with ...

ByCreative Enzymes


CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications

CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications

CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel ...

ByCD Formulation


Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

About DME Diabetic macular edema (DME) is a common complication in eyes of people living with diabetes. DME occurs when high levels of blood sugar lead to damaged blood vessels in the eye that leak fluid into the macula. ...

ByBayer AG


Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...

ByBayer AG


New data from pivotal studies with aflibercept 8 mg

New data from pivotal studies with aflibercept 8 mg

About nAMD and DME Neovascular (wet) age-related macular degeneration (nAMD) is an eye disease that progresses rapidly and if left untreated can lead to vision loss in as little as three months. nAMD is one of the leading causes of irreversible blindness and vision impairment around the world. nAMD may affect people as they age. It occurs when abnormal blood vessels grow and leak ...

ByBayer AG


Bayer submits aflibercept 8 mg for marketing authorization in Japan

Bayer submits aflibercept 8 mg for marketing authorization in Japan

About nAMD and DME Neovascular (wet) age-related macular degeneration (nAMD) is an eye disease that progresses rapidly and if left untreated can lead to vision loss in as little as three months. nAMD is one of the leading causes of irreversible blindness and vision impairment around the world. nAMD may affect people as they age. It occurs when abnormal blood vessels grow and leak ...

ByBayer AG


Alertgy Awarded Patent US20200217809A1 Apparatus For In Vivo Dielectric Spectroscopy

Alertgy Awarded Patent US20200217809A1 Apparatus For In Vivo Dielectric Spectroscopy

Alertgy has been granted a patent for their innovative and groundbreaking radio frequency sensor technology. The awarded patent, Apparatus for in vivo dielectric spectroscopy (US20200217809A1), focuses on sensor technology that is 100% non-invasive and continuously monitors blood glucose in a way that does not involve blood oxidase, but rather dielectric spectroscopy and radio frequency. As a ...

ByAlertgy


Alertgy Welcomes Executive-Level Director of Engineering

Alertgy Welcomes Executive-Level Director of Engineering

Alertgy, the biotech startup that’s in the race to be the first company to develop an entirely non-invasive glucose monitoring system is proud to welcome a new hire in the Engineering Department: Benjamin Freer joins Alertgy as Director of Engineering/Principal Sensor Engineer. “By far, the most exciting aspect of being on the Alertgy team is the opportunity to see a dream of mine ...

ByAlertgy


Alertgy Expands Into New Facility After Successful FlexTech Developer Partnership

Alertgy Expands Into New Facility After Successful FlexTech Developer Partnership

Alertgy is excited to announce that we have moved to a new facility! We are still in the process of organizing our new headquarters, but we wanted to share with you our newly expanded capabilities and our progress thus far. Alertgy is also pleased to announce that it has been awarded a Developers Agreement between Alertgy Inc. and SEMI – Flextech. SEMI is the global industry association ...

ByAlertgy


What’s Next For The Biotech Startup Alertgy and Their Non-Invasive Glucometer

What’s Next For The Biotech Startup Alertgy and Their Non-Invasive Glucometer

Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. By replacing commercial off-the-shelf components with custom built parts, Alertgy has been able to greatly reduce the size of its NICGM. Throughout the design process, Alertgy has aimed to ...

ByAlertgy


Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...

ByBayer AG


Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

About nAMD and DME Neovascular (wet) age-related macular degeneration (nAMD) is an eye disease that progresses rapidly and if left untreated can lead to vision loss in as little as three months. nAMD is one of the leading causes of irreversible blindness and vision impairment around the world. nAMD may affect people as they age. It occurs when abnormal blood vessels grow and leak ...

ByBayer AG


LifeScan’s Response to the Invasion of Ukraine

LifeScan’s Response to the Invasion of Ukraine

For over 40 years, LifeScan’s vision has been to create a world without limits for people with diabetes and related conditions, and this remains as strong today as ever, and perhaps when our support is needed most. Therefore, we are responding to the urgent humanitarian need for diabetes health medical supplies resulting from the invasion of Ukraine. As part of our longstanding commitment ...

ByLifeScan


World Diabetes Day

World Diabetes Day

Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. ...

ByNeurovalens Limited


New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize

New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize

Key Research Survey Findings: 52 percent of healthcare providers agreed motivation is a major barrier to patients adhering to blood glucose monitoring compared to only 10 percent of people with diabetes who agreed motivation is a major barrier. Healthcare providers claimed they are recommending blood glucose management apps to only 25 percent of their patients, while 55% of patients who ...

ByLifeScan

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT